• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP
【24h】

A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP

机译：一项由Aerobika OPEP管理的慢性阻塞性肺疾病（COPD）患者30天急性发作结局的真实研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionOscillating positive expiratory pressure (OPEP) devices may reduce chronic symptoms in patients with obstructive pulmonary disease (COPD); however, no real-world studies have been performed to evaluate the benefits of these devices. The objective of this study was to measure the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients treated with Aerobika, an OPEP device, vs. a matched control group in a real-world setting. MethodsThe study utilized data from the QuintilesIMS’ CDM hospital database. COPD patients treated with Aerobika OPEP between 9/2013 and 8/2015 were propensity score matched to COPD patients who did not use any positive expiratory pressure device. Severe exacerbation was defined as a hospital admission with a diagnosis for chronic bronchitis or COPD. Moderate-to-severe exacerbation was defined as a hospitalization or an ED visit with a diagnosis for chronic bronchitis or COPD. Exacerbations and costs were compared between cohorts at 30?days. A generalized linear model (GLM) was used to estimate the marginal effect of Aerobika OPEP on the cost of ED visits and hospitalizations due to COPD exacerbations. ResultsA total of 405 Aerobika OPEP patients were matched to 405 controls. At 30?days, 18.5% of subjects using the Aerobika OPEP vs. 25.7% of controls had a moderate-to-severe exacerbation ( p =?0.014); 13.8% of subjects with Aerobika OPEP vs. 19.0% of controls had a severe exacerbation ( p =?0.046). The mean per patient cost of moderate-to-severe exacerbations and severe exacerbations in the Aerobika OPEP group was significantly lower than controls ($2975 vs. $6065; p =?0.008, and $2838 vs. $5871; p =?0.009, respectively). In the GLM, the per-patient cost of moderate-to-severe exacerbations in the Aerobika OPEP group was 34% lower ( p =?0.012) than the control group. ConclusionsStudy findings suggest that using Aerobika OPEP as part of a treatment regimen may help reduce ED visits, hospital re-admissions and related costs in COPD patients who have a history of exacerbations.
机译：简介振荡性呼气正压（OPEP）装置可以减轻阻塞性肺疾病（COPD）患者的慢性症状;但是，尚未进行现实世界的研究来评估这些设备的优势。这项研究的目的是测量在现实环境中，使用OPEP装置Aerobika相对于对照组的COPD患者的早期（30天）中度至重度加重率和相关费用。方法该研究利用了QuintilesIMS CDM医院数据库中的数据。在9/2013至8/2015之间接受Aerobika OPEP治疗的COPD患者的倾向得分与未使用任何呼气正压设备的COPD患者相匹配。严重加重定义为入院时诊断为慢性支气管炎或COPD。中度至重度恶化定义为住院或急诊就诊，诊断为慢性支气管炎或COPD。比较两组患者在30天时的病情加重和费用。使用广义线性模型（GLM）来评估Aerobika OPEP对由于COPD恶化而导致的急诊就诊和住院费用的边际影响。结果405例Aerobika OPEP患者与405例对照相匹配。在第30天，使用Aerobika OPEP的受试者中有18.5％的受试者有25％的中度至重度加重（p =？0.014）;而使用Aerobika OPEP的受试者则为25.7％。 13.8％的Aerobika OPEP受试者与19.0％的对照受试者严重加重（p =？0.046）。 Aerobika OPEP组中每位患者的中至重度加重和重度加重的平均费用均显着低于对照组（分别为2975美元对6065美元; p = 0.008，2838美元与5871美元; p = 0.009; p = 0.009）。在GLM中，Aerobika OPEP组的每位患者中度至重度加重的费用比对照组低34％（p =？0.012）。结论研究结果表明，使用Aerobika OPEP作为治疗方案的一部分可能有助于减少有加重病史的COPD患者的ED访视，再次住院和相关费用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号